Oligogenic combinations associated with breast cancer risk in women under 53 years of age

Human Genetics

Volumn 116, Issue 3, 2005, Pages 208-221

  Aston, Christopher E ^a,b   Ralph, David A ^b   Lalo, Dominique P ^b   Manjeshwar, Sharmila ^a,b   Gramling, Bobby A ^b   DeFreese, Daniele C ^b   West, Amy D ^b   Branam, Dannielle E ^a   Thompson, Linda F ^a   Craft, Melissa A ^d   Mitchell, Debra S ^d   Shimasaki, Craig D ^b   Mulvihill, John J ^c   Jupe, Eldon R ^a,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b InterGenetics Incorporated   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d Breast Imaging of Oklahoma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CELL CYCLE PROTEIN; CYTOCHROME P450; GLUTATHIONE TRANSFERASE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SULFOTRANSFERASE; VITAMIN D RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC EPISTASIS; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 19944432169     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00439-004-1206-7     Document Type: Article

References (84)

1. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Pettersson K, Huhtaniemi I (2000) Genetic variant of luteinizing hormone and risk of breast cancer in older women. Cancer Epidemiol Biomarkers Prev 9:839-842 1:CAS:528:DC%2BD3cXmsVWjtbs%3D
2. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21:1-18
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130 10.1086/375033
4. Bell NH, Morrison NA, Nguyen TV, Eisman J, Hollis BW (2001) Apa I polymorphisms of the vitamin D receptor predict bone density of the lumbar spine and not racial difference in bone density in young men. J Lab Clin Med 137:133-140 10.1067/mlc.2001.112095
5. Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West D, Wright W, Ziogas A, Ross RK (2002) High breast cancer incidence rates among California teachers: Results from the California Teachers Study (United States). Cancer Causes Control 13:625-635 10.1023/A:1019552126105
6. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005-1011 1:CAS:528:DyaK2MXosVyqsrw%3D
7. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J (2004) Modification of breast cancer risk in young women by a polymorphic sequence in the Egfr gene. Cancer Res 64:7-12 1:CAS:528:DC%2BD2cXksl2jsg%3D%3D
8. Breslow RA, Ballard-Barbash R, Munoz K, Graubard BI (2001) Long-term recreational physical activity and breast cancer in the National Health and Nutrition Examination Survey I epidemiologic follow-up study. Cancer Epidemiol Biomarkers Prev 10:805-808 1:STN:280:DC%2BD3Mzos1Oruw%3D%3D
9. Bromberger JT, Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P (1997) Prospective study of the determinants of age at menopause. Am J Epidemiol 145:124-133 1:STN:280:ByiC2Mfps1w%3D
10. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA (1993) Family history, age, and risk of breast cancer. Prospective data from the nurses' health study. JAMA 270:338-343 10.1001/jama.270.3.338
11. Comings DE, Gade-Andavolu R, Cone L, Muhleman D, MacMurray JP (2003) A multigene test for the risk of sporadic breast carcinoma. Cancer 97:2160-2170 10.1002/cncr.11340
12. Cordell HJ (2002) Epistasis: What it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet 11:2463-2468 10.1093/hmg/11.20.2463
13. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR (1999) Association of a vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 83:723-726 1:CAS:528:DC%2BD3cXjtVyj
14. Davis S, Mirick DK, Stevens RG (2002) Residential magnetic fields and the risk of breast cancer. Am J Epidemiol 155:446-454 10.1093/aje/155.5.446
15. Decensi A, Johansson H, Miceli R, Mariani L, Camerini T, Cavadini E, Di Mauro MG, Barreca A, Gonzaga AG, Diani S, Sandri MT, De Palo G, Formelli F (2001) Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol Biomarkers Prev 10:1047-1053 1:CAS:528:DC%2BD3MXotVyktbs%3D
16. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843-854 1:CAS:528:DyaK1MXns1CrtLw%3D
17. Evans DG, Birch JM, Thorneycroft M, McGown G, Lalloo F, Varley JM (2002) Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet 39:941-944 10.1136/jmg.39.12.941
18. Falany CN (1997) Enzymology of human cytosolic sulfotransferases. FASEB J 11:206-216 1:CAS:528:DyaK2sXhvVGmtLw%3D
19. Feigelson HS, Henderson BE (2000) Future possibilities in the prevention of breast cancer: Role of genetic variation in breast cancer prevention. Breast Cancer Res 2:277-282 10.1186/bcr69
20. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585-587 1:CAS:528:DyaK1cXht1ant7c%3D
21. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61:785-789 1:CAS:528:DC%2BD3MXht1Gmt7g%3D
22. Ferrari S, Rizzoli R, Chevalley T, Slosman D, Eisman JA, Bonjour JP (1995) Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density. Lancet 345:423-424 10.1016/S0140-6736(95)90404-2
23. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J (2003) Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 164:239-246 1:CAS:528:DC%2BD3sXnsVygur4%3D
24. Fu YP, Yu JC, Cheng TC, Lou MA, Hsu GC, Wu CY, Chen ST, Wu HS, Wu PE, Shen CY (2003) Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: A multigenic study on cancer susceptibility. Cancer Res 63:2440-2446 1:CAS:528:DC%2BD3sXjslehsLY%3D
25. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122 1:CAS:528:DyaK2cXmslers70%3D
26. Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, Skurnick J (2001) Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 153:865-874 10.1093/aje/153.9.865
27. Goodman JE, Lavigne JA, Wu K, Helzlsouer KJ, Strickland PT, Selhub J, Yager JD (2001) COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 22:1661-1665 10.1093/carcin/22.10.1661
28. Gudmundsdottir K, Tryggvadottir L, Eyfjord JE (2001) GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 10:1169-1173 1:CAS:528:DC%2BD3MXptFWqu7o%3D
29. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59:1015-1020 1:CAS:528:DyaK1MXhslemtbs%3D
30. Hall JA, Murphy DC, Hall BR, Hall KA (1993) Mammographic abnormalities and the detection of carcinoma of the breast. Am J Obstet Gynecol 168:1677-1680 1:STN:280:ByyA3cvktlw%3D
31. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Watson M, Comstock GW, Bell D (1998) Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 90:512-518 10.1093/jnci/90.7.512
32. Hou MF, Tien YC, Lin GT, Chen CJ, Liu CS, Lin SY, Huang TJ (2002) Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 74:1-7
33. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility. Cancer Res 59:4870-4875 1:CAS:528:DyaK1MXmslWktLw%3D
34. Iannone MA, Taylor JD, Chen J, Li MS, Rivers P, Slentz-Kesler KA, Weiner MP (2000) Multiplexed single nucleotide polymorphism genotyping by oligonucleotide ligation and flow cytometry. Cytometry 39:131-140 10.1002/(SICI)1097-0320(20000201)39:2<131::AID-CYTO6>3.3.CO;2-L
35. Johansson AS, Stenberg G, Widersten M, Mannervik B (1998) Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 278:687-698 10.1006/jmbi.1998.1708
36. Johnson N, Lancaster T, Fuller A, Hodgson SV (1995) The prevalence of a family history of cancer in general practice. Fam Pract 12:287-289 1:STN:280:BymC3MrkvFY%3D
37. Jong MM de, Nolte IM, Meerman GJ te, Graaf WT van der, Oosterwijk JC, Kleibeuker JH, Schaapveld M, Vries EG de (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39:225-242 10.1136/jmg.39.4.225
38. Jupe ER, Badgett AA, Neas BR, Craft MA, Mitchell DS, Resta R, Mulvihill JJ, Aston CE, Thompson LF (2001) Single nucleotide polymorphism in prohibitin 3′ untranslated region and breast-cancer susceptibility. Lancet 357:1588-1589 10.1016/S0140-6736(00)04747-4
39. Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A (1998) Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol 51:1271-1276 10.1016/S0895-4356(98)00119-X
40. Kong S, Wei Q, Amos CI, Lynch PM, Levin B, Zong J, Frazier ML (2001) Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 93:1106-1108 10.1093/jnci/93.14.1106
41. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996) Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250 1:CAS:528:DyaK28XksFemsLw%3D
42. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57:5493-5497 1:CAS:528:DyaK2sXotVGntr4%3D
43. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78-85 10.1056/NEJM200007133430201
44. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA (2000) XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis 21:551-555 10.1093/carcin/21.4.551
45. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922-929 10.1001/jama.279.12.922
46. Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER (2003) Tumor suppression by the prohibitin gene 3′ untranslated region RNA in human breast cancer. Cancer Res 63:5251-5256 1:CAS:528:DC%2BD3sXntlektLY%3D
47. McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE (2001) Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61:8393-8394 1:CAS:528:DC%2BD3MXptFCktL0%3D
48. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71 1:CAS:528:DyaK2MXhtF2ns70%3D
49. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A (2001) Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:635-640 1:CAS:528:DC%2BD3MXlt1Srt7o%3D
50. Morgan J, Siegel D, Ross D (1999) A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H;quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA 96:8150-8155
51. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279:915-921 10.1001/jama.279.12.915
52. Palli D, Russo A, Masala G, Saieva C, Guarrera S, Carturan S, Munnia A, Matullo G, Peluso M (2001) DNA adduct levels and DNA repair polymorphisms in traffic-exposed workers and a general population sample. Int J Cancer 94:121-127 10.1002/ijc.1433
53. Peto J, Mack TM (2000) High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 26:411-414
54. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33-36
55. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298-304 10.1006/bbrc.1997.7466
56. Rutter JL, Chatterjee N, Wacholder S, Struewing J (2003) The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 14:694-700 10.1097/01.ede.0000083227.74669.7b
57. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, Hara M, Saito I (1998) Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 16:1701-1712 10.1038/sj.onc.1201691
58. Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer-susceptibility genes? Am J Hum Genet 60:486-495 1:CAS:528:DyaK2sXhvFGjtLk%3D
59. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K (2000) Phenol sulfotransferases: Hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 60:6859-6863 1:CAS:528:DC%2BD3MXjsVKqsw%3D%3D
60. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984-2986 1:CAS:528:DyaK38Xkt1equ74%3D
61. Siegel D, McGuinness SM, Winski SL, Ross D (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:qUinone oxidoreductase 1. Pharmacogenetics 9:113-121
62. Slattery ML, Kerber RA (1993) A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 270:1563-1568 10.1001/jama.270.13.1563
63. Smith MT, Wang Y, Kane E, Rollinson S, Wiemels JL, Roman E, Roddam P, Cartwright R, Morgan G (2001) Low NAD(P)H:qUinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97:1422-1426 10.1182/blood.V97.5.1422
64. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP 3rd, Foster RS Jr, Hendrick E, Eyre HJ, Sener S (2003) American Cancer Society guidelines for breast cancer screening: Update 2003. CA Cancer J Clin 53:141-169 12809408
65. Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G (2000) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 92:1674-1681 10.1093/jnci/92.20.1674
66. Tang D, Cho S, Rundle A, Chen S, Phillips D, Zhou J, Hsu Y, Schnabel F, Estabrook A, Perera FP (2002) Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res Treat 75:159-166 10.1023/A:1019693504183
67. Taylor JD, Briley D, Nguyen Q, Long K, Iannone MA, Li MS, Ye F, Afshari A, Lai E, Wagner M, Chen J, Weiner MP (2001) Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques 30:661-669
68. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB (1998) Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 58:2107-2110 1:CAS:528:DyaK1cXjt12htrw%3D
69. Tommasi S, Fedele V, Lacalamita R, Crapolicchio A, Perlino E, Bellizzi A, Paradiso A (2004) Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett 209:215-222 10.1016/j.canlet.2003.12.014
70. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC (2003) Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12:332-338
71. Vodicka P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, Dusinska M, Kuricova M, Zamecnikova M, Musak L, Buchancova J, Norppa H, Hirvonen A, Vodickova L, Naccarati A, Matousu Z, Hemminki K (2004) Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25:757-763 10.1093/carcin/bgh064
72. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O, Kato T (2002) Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23:257-264 10.1093/carcin/23.2.257
73. Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, Tsuchiya N, Sato K, Ohyama C, Nakamura A, Ogawa O, Kato T (2003) Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103:116-120 10.1002/ijc.10793
74. Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB (2000) Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res 60:2348-2350 1:CAS:528:DC%2BD3cXjtV2qsbc%3D
75. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998) Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19:275-280 10.1093/carcin/19.2.275
76. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105-112 1:CAS:528:DyaK2sXhs1Kht70%3D
77. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-791 10.1038/378789a0
78. Wrensch M, Chew T, Farren G, Barlow J, Belli F, Clarke C, Erdmann CA, Lee M, Moghadassi M, Peskin-Mentzer R, Quesenberry CP Jr, Souders-Mason V, Spence L, Suzuki M, Gould M (2003) Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res 5:R88-R102 10.1186/bcr605
79. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412-417 10.1093/jnci/92.5.412
80. Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD (2003) Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet 72:636-649 10.1086/367923
81. Ye Z, Parry JM (2002) The CYP17 Msp A1 polymorphism and breast cancer risk: A meta-analysis. Mutagenesis 17:119-126 10.1093/mutage/17.2.119
82. Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR (2001a) Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:89-94 11219777
83. Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS, Frazier ML, Spitz MR, Wei Q (2001b) Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: A case-control study. Carcinogenesis 22:1195-1199 10.1093/carcin/22.8.1195
84. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, Awasthi S, Awasthi YC (1994) Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 224:893-899 1:CAS:528:DyaK2cXlvF2itLg%3D